Effect of KATP drugs on electrophysiological and hemodynamic variables
| Control | Drug | |
|---|---|---|
| Refractory period (msec) | ||
| Glibenclamide (n = 17) | 122.6 ± 2.0 | 124.4 ± 2.3 |
| Pinacidil (n = 14) | 120.0 ± 2.0 | 110.0 ± 2.02-a |
| HMR 1883 (n = 10) | 120.7 ± 2.0 | 121.4 ± 2.1 |
| HR (beats/min) | ||
| Glibenclamide | 121.3 ± 7.3 | 107.9 ± 7.7 |
| Pinacidil | 122.1 ± 5.9 | 165.1 ± 13.62-a |
| HMR 1883 | 118.4 ± 6.6 | 113.7 ± 6.1 |
| PR interval (msec) | ||
| Glibenclamide | 100.6 ± 4.7 | 109.2 ± 6.2 |
| Pinacidil | 113.6 ± 6.6 | 91.4 ± 3.62-a |
| HMR 1883 | 105.2 ± 3.6 | 100.2 ± 2.8 |
| QTc interval (msec) | ||
| Glibenclamide | 265.2 ± 4.7 | 266.3 ± 10.2 |
| Pinacidil | 283.2 ± 15.1 | 273.1 ± 13.8 |
| HMR 1883 | 262.2 ± 7.5 | 271.6 ± 9.4 |
| LVSP (mm Hg) | ||
| Glibenclamide (n = 16) | 130.2 ± 6.9 | 131.7 ± 4.2 |
| Pinacidil (n = 12) | 136.7 ± 5.2 | 119.9 ± 5.82-a |
| HMR 1883 (n = 9) | 127.2 ± 4.3 | 128.3 ± 6.0 |
| Left ventricular dP/dt maximum (mm Hg/sec) | ||
| Glibenclamide | 3255 ± 272.7 | 2278 ± 195.82-a |
| Pinacidil | 3243 ± 294.6 | 3154 ± 518.0 |
| HMR 1883 | 3532 ± 220.1 | 3225 ± 183.2 |
| Mean CBF (ml/min) | ||
| Glibenclamide (n = 11) | 32.7 ± 2.9 | 23.4 ± 2.32-a |
| Pinacidil (n = 7) | 27.8 ± 2.6 | 72.5 ± 9.72-a |
| HMR 1883 (n = 10) | 34.4 ± 4.9 | 33.8 ± 3.4 |
↵2-a P < .01 Control vs. drug.